AI Article Synopsis
- Post-stem cell transplant (SCT) maintenance therapy is being explored as a way to improve outcomes for patients with peripheral T-cell lymphomas (PTCL), as relapse after SCT is common.
- Recent studies of agents like romidepsin, brentuximab vedotin, duvelisib, and pembrolizumab show promise in reducing relapse rates post-SCT.
- Ongoing trials continue to evaluate the effectiveness of these maintenance therapies, suggesting that they could be a significant strategy in managing PTCL.
Article Abstract
Purpose Of Review: Given the poor outcomes for peripheral T-cell lymphomas (PTCL), stem cell transplant (SCT) remains an important therapeutic approach. Post-SCT relapse is common and maintenance therapy post-SCT is increasingly being utilized. Here we review the use of post-SCT maintenance therapy for PTCL patients.
Recent Findings: Maintenance therapy is increasingly utilized to decrease post-SCT relapse and improve outcomes in PTCL. Ongoing and completed post-SCT maintenance trials utilizing agents such as romidepsin, brentuximab vedotin, duvelisib, and pembrolizumab have shown efficacy in decreasing relapse. Further, additional agents with efficacy in PTCL have emerged that may inform future maintenance approaches. Maintenance therapy is a promising approach to maintain response after SCT in PTCL. While several trials are ongoing to evaluate maintenance therapy in PTCL, current data suggests this may be an effective method to decrease post-SCT relapse.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568030 | PMC |
| http://dx.doi.org/10.1007/s11899-024-00743-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!